StockData
Alterity Therapeutics Ltd logo

Alterity Therapeutics Ltd (ATHE) stock

ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Aug 28, 2026Score 5/30
$1.96+0.00 (0.00%)

Close on Nov 16, 2026Market cap $35.53MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
A$51.67M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
-43.59%

Fundamentals

Free cash flow
-A$22.52M

Trading

Previous close
$1.96
Open
$1.96
Day's range
$1.89 – $2.05
Volume
13,410
Average volume (20 days)
233,537
Beta (5 years)
0.95
RSI (14 days)
31.9
Volatility (1 year)
69.2%
Relative volume
0.20×
WACC
9.9%

Market cap history

Month-end market cap since 2016, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodATHES&P 500DifferenceATHE per yearS&P 500 per year
1 month-25.2%-3.1%−22.1 pts
3 months-59.1%-4.5%−54.6 pts
Year to date-36.4%+9.4%−45.7 pts
1 year-49.0%+11.3%−60.3 pts
3 years-16.6%+70.4%−87.0 pts-5.9%+19.4%
5 years-82.7%+68.6%−151.2 pts-29.6%+11.0%
10 years-93.3%+297.7%−391.0 pts-23.7%+14.8%

Twelve years at a glance

Fiscal years 2015 to 2026, AUD

Revenue

–

Net income

–

EPS, diluted

–

Free cash flow

-A$22.52M
Reported period

Press releases

Releases Alterity Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Alterity Therapeutics

Pharmaceutical Preparations

Alterity Therapeutics Limited is a clinical-stage biotechnology company focused on creating treatments for neurodegenerative conditions. The company utilizes a proprietary chemical library and platform technology aimed at redistributing excess labile iron and addressing protein aggregation in the central nervous system. Its lead oral drug candidate, ATH434, is designed to reduce alpha-synuclein pathology and preserve neurons, with primary clinical development focused on Multiple System Atrophy, alongside research in Parkinson’s disease and other disorders.

Company profile, executives and history

Alterity Therapeutics stock: common questions

What is Alterity Therapeutics's stock price?

ATHE closed at $1.96 on Nov 16, 2026, up 0.00% on the day.

What is Alterity Therapeutics's market cap?

Alterity Therapeutics was worth $35.53M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

Does Alterity Therapeutics pay a dividend?

No. Alterity Therapeutics has not paid a cash dividend over the last twelve months.

How has ATHE stock performed over the past year?

Including dividends, ATHE returned -49.0% over the past year, against +11.3% for the S&P 500.

Who are Alterity Therapeutics's competitors?

Companies most similar to Alterity Therapeutics by business, industry and size include GANX, CRVO, CLNN, ANVS, SER.

See a number that looks wrong?